A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients With B7-H3-Expressing Relapsed or Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Enoblituzumab (Primary)
- Indications Ewing's sarcoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Adverse reactions
- Sponsors MacroGenics
- 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 31 Jan 2017 Status changed from active, no longer recruiting to recruiting.
- 05 Jan 2017 Status changed from not yet recruiting to active, no longer recruiting.